Paroxetine versus other anti-depressive agents for depression

Paroxetine versus other anti-depressive agents for depression

Bibliografski detalji
Glavni autori:	Purgato, M, Papola, D, Gastaldon, C, Trespidi, C, Magni, L, Rizzo, C, Furukawa, T, Watanabe, N, Cipriani, A, Barbui, C
Format:	Journal article
Izdano:	2014

Slični predmeti

Fluoxetine versus other types of pharmacotherapy for depression
od: Magni, L, i dr.
Izdano: (2013)

Citalopram versus other anti-depressive agents for depression.
od: Cipriani, A, i dr.
Izdano: (2012)

Duloxetine versus other anti-depressive agents for depression.
od: Cipriani, A, i dr.
Izdano: (2012)

Fluvoxamine versus other anti-depressive agents for depression.
od: Omori, I, i dr.
Izdano: (2010)

Mirtazapine versus other antidepressive agents for depression.
od: Watanabe, N, i dr.
Izdano: (2011)

Milnacipran versus other antidepressive agents for depression.
od: Nakagawa, A, i dr.
Izdano: (2009)

Escitalopram versus other antidepressive agents for depression.
od: Cipriani, A, i dr.
Izdano: (2009)

Sertraline versus other antidepressive agents for depression.
od: Cipriani, A, i dr.
Izdano: (2009)

Sertraline versus other antidepressive agents for depression.
od: Cipriani, A, i dr.
Izdano: (2010)

Sertraline versus other antidepressive agents for depression
od: Cipriani, A, i dr.
Izdano: (2010)

Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials.
od: Barbui, C, i dr.
Izdano: (2008)

Fluoxetine versus other types of pharmacotherapy for depression
od: Cipriani, A, i dr.
Izdano: (2009)

Fluoxetine versus other types of pharmacotherapy for depression.
od: Cipriani, A, i dr.
Izdano: (2005)

Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.
od: Watanabe, N, i dr.
Izdano: (2008)

Brexpiprazole versus placebo or other antidepressive agents for treating depression
od: Ralovska, S, i dr.
Izdano: (2021)

Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders
od: D. Papola, i dr.
Izdano: (2024-04-01)

Safety of psychotropic medications in people with COVID-19
od: G. Ostuzzi, i dr.
Izdano: (2021-04-01)

Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.
od: Nakagawa, A, i dr.
Izdano: (2008)

Long-term treatment of depression with antidepressants: a systematic narrative review.
od: Furukawa, T, i dr.
Izdano: (2007)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
od: Kishi T, i dr.
Izdano: (2017-01-01)

Depressive disorder needs an evidence base commensurate with its public health importance.
od: Geddes, J, i dr.
Izdano: (2007)

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
od: Chen JW, i dr.
Izdano: (2018-02-01)

Specific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression.
od: Benjamin D Schalet, i dr.
Izdano: (2016-01-01)

Which psychotherapy is effective in panic disorder? Findings and reflections from a systematic network meta-analysis
od: D. Papola, i dr.
Izdano: (2021-04-01)

Venlafaxine for major depression.
od: Cipriani, A, i dr.
Izdano: (2007)

Suicide, depression, and antidepressants.
od: Cipriani, A, i dr.
Izdano: (2005)

Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice.
od: Cipriani, A, i dr.
Izdano: (2007)

Novel melatonin-based treatments for major depression.
od: Barbui, C, i dr.
Izdano: (2012)

Comparative efficacy and acceptability of psychosocial interventions for PTSD, depression, and anxiety in asylum seekers, refugees, and other migrant populations: a systematic review and network meta-analysis of randomised controlled studiesResearch in context
od: Giulia Turrini, i dr.
Izdano: (2025-01-01)

Paroxetine treatment in an animal model of depression improves sperm quality
od: Reyhane Aghajani, i dr.
Izdano: (2022-01-01)

Paroxetine treatment in an animal model of depression improves sperm quality.
od: Reyhane Aghajani, i dr.
Izdano: (2022-01-01)

Why it is important to include unpublished data in systematic reviews.
od: Trespidi, C, i dr.
Izdano: (2011)

Benzodiazepines and risk of dementia: true association or reverse causation?
od: Barbui, C, i dr.
Izdano: (2013)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
od: Aoki A, i dr.
Izdano: (2014-09-01)

Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
od: Watanabe, N, i dr.
Izdano: (2010)

Alpha oscillations predict paroxetine response to low sexual desire in depression
od: Mehmet Kemal Arıkan, i dr.
Izdano: (2021-12-01)

Identification and investigation of depression-related molecular subtypes in inflammatory bowel disease and the anti-inflammatory mechanisms of paroxetine
od: Lijun Ning, i dr.
Izdano: (2023-02-01)

Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis.
od: Omori, I, i dr.
Izdano: (2009)

No interaction between plasma IL-6 and MHPG in major depression treated with paroxetine
od: Reiji Yoshimura, i dr.
Izdano: (2022-09-01)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
od: Kamijima K, i dr.
Izdano: (2013-04-01)